Qiagen N.V. (NYSE:QGEN) Given Average Recommendation of “Hold” by Brokerages

Shares of Qiagen N.V. (NYSE:QGEN) have received a consensus recommendation of “Hold” from the fourteen ratings firms that are presently covering the company, MarketBeat reports. Nine equities research analysts have rated the stock with a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $43.9250.

A number of research firms have recently commented on QGEN. JPMorgan Chase & Co. lifted their target price on Qiagen from $45.00 to $50.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Berenberg Bank set a $45.50 price target on shares of Qiagen and gave the company a “hold” rating in a research report on Tuesday, July 14th. Morgan Stanley raised shares of Qiagen from an “overweight” rating to an “overweight” rating and lifted their price objective for the stock from $40.00 to $42.00 in a research report on Tuesday, June 23rd. Barclays set a $40.00 target price on shares of Qiagen and gave the company an “equal weight” rating in a research note on Friday, August 7th. Finally, Citigroup reissued a “neutral” rating and set a $45.00 target price (up from $38.00) on shares of Qiagen in a research report on Monday, August 10th.

Qiagen Stock Performance

Shares of QGEN opened at $43.35 on Tuesday. The stock has a 50 day moving average of $41.51 and a 200 day moving average of $40.54. The company has a market capitalization of $8.93 billion, a price-to-earnings ratio of 22.21, a PEG ratio of 4.29 and a beta of 0.63. Qiagen has a 12 month low of $32.53 and a 12 month high of $57.81. The company has a current ratio of 2.85, a quick ratio of 2.31 and a debt-to-equity ratio of 0.48.

Qiagen (NYSE:QGEN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.02. The business had revenue of $535.04 million for the quarter, compared to analysts’ expectations of $527.50 million. Qiagen had a return on equity of 14.47% and a net margin of 19.49%.The business’s revenue was up .2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.60 earnings per share. Qiagen has set its FY 2026 guidance at 2.430- EPS. As a group, sell-side analysts forecast that Qiagen will post 2.43 earnings per share for the current year.

Institutional Trading of Qiagen

Large investors have recently bought and sold shares of the company. Baader Bank Aktiengesellschaft bought a new position in shares of Qiagen during the 1st quarter worth $1,368,000. Vanguard Group Inc. raised its stake in Qiagen by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 9,542,944 shares of the company’s stock valued at $433,871,000 after acquiring an additional 118,135 shares during the period. The Manufacturers Life Insurance Company purchased a new stake in Qiagen during the first quarter valued at about $2,518,000. Janus Henderson Group PLC purchased a new stake in Qiagen during the first quarter valued at about $14,647,000. Finally, Handelsbanken Fonder AB bought a new position in Qiagen during the second quarter worth about $2,909,000. 70.00% of the stock is owned by hedge funds and other institutional investors.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library?preparation kits and proteomics solutions.